Title

26607 Proactive management using Cal/BD foam in patients with plaque psoriasis prolongs time with a health-related quality of life improvement, compared with reactive management

Authors

Linda F. Stein Gold, Henry Ford HealthFollow
Ahmad Jalili
Dominique Lons Danic
Nanna Nyholm
Henrik Thoning
Piergiacomo Calzavara-Pinton

Recommended Citation

Gold LS, Jalili A, Danic DL, Nyholm N, Thoning H, and Calzavara-Pinton P. 26607 Proactive management using Cal/BD foam in patients with plaque psoriasis prolongs time with a health-related quality of life improvement, compared with reactive management. J Am Acad Dermatol 2021; 85(3):AB109.

Document Type

Conference Proceeding

Publication Date

9-1-2021

Publication Title

Journal of the American Academy of Dermatology

Abstract

Introduction: The Phase III PSO-LONG study (NCT02899962) showed that proactive (PM) vs reactive management (RM) using calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam for up to 52 weeks in adults with psoriasis, resulted in superior efficacy. The patient-reported outcome measure Dermatology Life Quality Index (DLQI) evaluates patient-perception of psoriasis on health-related quality of life (HRQoL). In this post hoc analysis of PSO-LONG we evaluate whether initial DLQI responses, obtained following open-label Cal/BD foam treatment, were better sustained using subsequent PM or RM.

Methods: PSO-LONG included an initial 4-week open-label phase (OLP) (once-daily Cal/BD foam) and a 52-week, double-blind, maintenance phase (MP) where patients were randomized to twice-weekly Cal/BD or vehicle foam (PM or RM, respectively), with 4-weeks once-daily Cal/BD foam rescue treatment for relapse (Physician’s Global Assessment [PGA] ≥2). The proportion of patients achieving DLQI = 0/1 following OLP was assessed during MP to evaluate how long patients sustained initially gained responses. Survival analysis curves and hazard ratios (HR) for time with response in each group, were evaluated.

Results: The analysis included 521 patients with predominantly PGA-moderate psoriasis (85.2%). During OLP, 49% of patients achieved DLQI = 0/1. During MP, RM vs PM was associated with almost double the risk (hazard) of losing DLQI = 0/1 (HR: 1.92; P ˂.001) and median time to lost response was almost 3.5 times shorter (57 vs 197 days, respectively).

Conclusion: In a subset of patients achieving a DLQI = 0/1 HRQoL response following initial open-label Cal/BD foam, subsequent PM with Cal/BD foam significantly prolonged time with DLQI response vs RM.

Volume

85

Issue

3

First Page

AB109